RLAY Relay Therapeutics, Inc.
Executive Summary
Relay Therapeutics saw a strong net buying cluster in Q3 2024, with 12 institutional buyers adding $71.5M versus 7 sellers reducing just $6.1M. Notable activity includes Norges Bank adding $20.3M, Citadel doubling its position with $13.0M, and Adage Capital initiating a new $11.7M stake. Net buying bias suggests institutional conviction in the R&D pipeline and upcoming catalysts, despite mixed prior quarter performance.
Key Financial Metrics
Institutional Positions
Net institutional flow: $65.1M
▲ Buyers (12)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Norges Bank | ADD | +78.3% | $41.9M | $20.3M |
| Citadel | DOUBLED | +150.1% | $20.6M | $13.0M |
| Adage Capital Partners Gp | NEW | — | $11.7M | $11.7M |
| Walleye Capital | DOUBLED | +6659.2% | $12.9M | $12.7M |
| Franklin Resources | DOUBLED | +3883.8% | $9.4M | $9.2M |
▼ Sellers (7)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Alliancebernstein | NEAR_EXIT | -75.4% | $3.7M | -$2.7M |
| Federated Hermes | NEAR_EXIT | -97.5% | $2.0M | -$2.0M |
| Hightower Advisors | TRIM | -48.9% | $2.0M | -$885.0K |
Actionable Insight
The Q3 cluster shows elite institutional accumulation ahead of RLAY's key pipeline catalysts (likely RLY-2608 Phase 1/2 data). Traders should watch for upcoming data readouts, especially at medical meetings, as this inflow suggests conviction in positive outcomes. The ~$65M net buy is large relative to RLAY's ~$0.5B market cap (~13% of float equivalent). Monitor insider trading and future 13F filings for confirmation or unwinding.
Key Facts
- 12 institutional buyers added a net $71.5M in Q3 2024.
- 7 sellers reduced holdings by a combined ~$6.1M, a small fraction of buying.
- Norges Bank (sovereign) added ~$20.3M, its largest dollar increase.
- Citadel (quant) doubled its stake, adding ~$13.0M.
- Adage Capital initiated a new $11.7M position.
- Walleye Capital and Franklin Resources also posted large-ratio increases.
- Cluster is dominated by active managers and sovereign/quants, not passive rebalancing.
- Sellers were mostly trimming small positions (AllianceBernstein, Federated Hermes near-exits).
Financial Impact
12 buyers accumulated a net $71.5M; 7 sellers reduced $6.1M, resulting in ~$65.4M net institutional inflow for the quarter.
Risk Factors
- 13F filings are 45 days stale; positions may have been partially or fully reversed since quarter-end.
- HISTORICAL PERFORMANCE shows mixed T+20 outcomes on prior bullish reads (win rate 50%), caution warranted.
- Biotech binary risk: pipeline failure would negate institutional thesis and likely drive sharp declines.
Market Snapshot
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-RLAY-2024-Q3 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
8d ago
|
Institutional Cluster
| $14.81 $14.96 | ▲ +1.01% | ▼ −0.75% | — |
|
May 21, 2026
4w ago
|
8-K
| $13.53 $14.17 | ▼ −4.73% | ▼ −4.14% | — |
|
May 21, 2026
4w ago
|
Press Release
| $13.66 $13.53 | ▲ +0.95% | ▲ +1.40% | — |
|
May 19, 2026
4w ago
|
424B5
| $13.02 $13.66 | ▼ −4.92% | ▼ −4.72% | — |
|
May 19, 2026
4w ago
|
Press Release
| $13.02 $13.66 | ▼ −4.92% | ▼ −4.72% | — |
|
May 19, 2026
4w ago
|
Press Release
| $12.07 $13.02 | ▲ +7.87% | ▲ +6.83% | — |
|
Apr 27, 2026
7w ago
|
8-K
| $14.95 $13.03 | ▼ −12.84% | ▼ −12.36% | — |
|
Apr 27, 2026
7w ago
|
Press Release
| $14.95 $13.03 | ▼ −12.84% | ▼ −12.36% | — |
|
Mar 16, 2026
13w ago
|
Press Release
| $10.13 $10.26 | ▲ +1.28% | ▲ +1.01% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access